In palliative and end-of-life care, medical morphine is often the gold standard for managing severe pain and dyspnea, providing comfort and dignity to patients with advanced illnesses. Its rapid onset, predictable pharmacokinetics, and versatility in formulation make it indispensable in hospice settings, hospitals, and increasingly, home-based care.

The market was valued at USD 24.76 billion in 2024 and is projected to reach USD 53.22 billion by 2035, growing at a CAGR of approximately 7.2%. Growth is driven by the rising prevalence of chronic pain conditions, an aging global population, increasing cancer incidence, and advancements in pain management protocols that emphasize balanced, multimodal approaches.

Injectable morphine is widely used in acute and hospice settings for rapid symptom control, while oral formulations (including extended-release tablets and solutions) support long-term management in outpatient and home care. Innovations in delivery systems—such as patient-controlled analgesia (PCA) pumps and transdermal patches—are enhancing comfort and reducing caregiver burden.

Regionally, North America and Europe lead in palliative care infrastructure, but access remains uneven globally. Asia-Pacific, Latin America, and Africa are seeing increased investment in palliative care programs, driven by rising cancer rates and advocacy for pain relief as a human right.

Key players include Purdue Pharma, Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries, Mundipharma, Hikma Pharmaceuticals, Amgen, Sandoz, and Boehringer Ingelheim. Strategies focus on expanding access in underserved regions, developing patient-friendly formulations, and supporting palliative care training and education initiatives.

Read more: Medical Morphine Market Size, Share, Trends, Report 2035

People Also Ask

Q1. Why is morphine preferred in palliative care?
Morphine is preferred due to its rapid onset, predictable effects, versatility in formulation (injectable, oral, transdermal), and well-established protocols for managing severe pain and dyspnea in advanced illness.

Q2. How is access to morphine improving in low-income countries?
Access is improving through advocacy by global health organizations, government initiatives to streamline regulations, and partnerships with pharmaceutical companies to ensure affordable supply for palliative care programs.

Tags: medical morphine, palliative care, end-of-life care, hospice, pain relief, global health access